Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial

被引:28
|
作者
Thorleifsdottir, Ragna Hlin [1 ,2 ]
Sigurdardottir, Sigrun Laufey [3 ]
Sigurgeirsson, Bardur [1 ]
Olafsson, Jon Hjaltalin [1 ]
Sigurdsson, Martin Ingi [4 ]
Petersen, Hannes [5 ]
Gudjonsson, Johann Eli [6 ]
Johnston, Andrew [6 ]
Valdimarsson, Helgi [3 ]
机构
[1] Univ Iceland, Dermatol Sect, Fac Med, Reykjavik, Iceland
[2] Uppsala Univ, Dept Med Sci, Dermatol, Uppsala, Sweden
[3] Landspitali Natl Univ Hosp Iceland, Dept Immunol, Reykjavik, Iceland
[4] Landspitali Natl Univ Hosp Iceland, Dept Anesthesiol & Crit Care, Reykjavik, Iceland
[5] Landspitali Natl Univ Hosp Iceland, Dept Otolaryngol Head & Neck Surg, Reykjavik, Iceland
[6] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI USA
关键词
chronic plaque psoriasis; streptococcal throat infection; tonsillectomy; health-related quality of life; Psoriasis Disability Index; Psoriasis Life Stress Inventory; QUALITY-OF-LIFE; STREPTOCOCCAL THROAT INFECTIONS; RECALCITRANT PSORIASIS; GUTTATE PSORIASIS; PERIPHERAL-BLOOD; VULGARIS; CELLS; PATHOGENESIS; IMPROVEMENT; ONSET;
D O I
10.2340/00015555-2562
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a chronic inflammatory skin disease with profound effects on patients' health-related quality of life (HRQoL). Twenty-nine patients with plaque psoriasis and a history of streptococcal-associated psoriasis exacerbations were randomly assigned to tonsillectomy (n = 15) or control (n = 14) groups and followed for 24 months. Patients were evaluated with the Psoriasis Disability Index, Psoriasis Life Stress Inventory and Psoriasis Area and Severity Index. HRQoL and psoriasis-related stress improved significantly in the tonsillectomy group compared with the control group (p = 0.037 and p = 0.002, respectively), with a mean 50% improvement in HRQoL and a mean 59% improvement in psoriasis-induced stress. Clinical improvement correlated significantly with improved HRQoL (r = 0.297, p = 0.008) and psoriasis-related stress (r = 0.310, p = 0.005). Of the tonsillectomized patients, 87% concluded that the procedure was worthwhile. Tonsillectomy may improve quality of life for selected patients with plaque psoriasis.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 50 条
  • [31] Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naive patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
    Thaci, D.
    Soliman, A. M.
    Eyerich, K.
    Pinter, A.
    Sebastian, M.
    Unnebrink, K.
    Rubant, S.
    Williams, D. A.
    Weisenseel, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (08) : 1686 - 1691
  • [32] Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept
    Griffiths, C. E. M.
    Sterry, W.
    Brock, F.
    Dilleen, M.
    Stefanidis, D.
    Germain, J. M.
    Mallbris, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) : 230 - 238
  • [33] Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
    Mark G. Lebwohl
    Andrew Blauvelt
    Alan Menter
    Kim A. Papp
    Scott Guenthner
    Radhakrishnan Pillai
    Robert J. Israel
    Abby Jacobson
    American Journal of Clinical Dermatology, 2019, 20 : 863 - 871
  • [34] Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
    Lebwohl, Mark G.
    Blauvelt, Andrew
    Menter, Alan
    Papp, Kim A.
    Guenthner, Scott
    Pillai, Radhakrishnan
    Israel, Robert J.
    Jacobson, Abby
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (06) : 863 - 871
  • [35] Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis
    Revicki, D.
    Willian, M. K.
    Saurat, J. -H.
    Papp, K. A.
    Ortonne, J. -P.
    Sexton, C.
    Camez, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) : 549 - 557
  • [36] Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis
    Afach, Sivem
    Le Cleach, Laurence
    Sbidian, Emilie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB103 - AB103
  • [37] Response in the placebo group in randomized controlled trials for moderate-to-severe psoriasis
    Afach, S.
    Le Cleach, L.
    Sbidian, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 15 - 15
  • [38] Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
    Wang, Juncheng
    Zhu, Qingli
    Li, Feng
    Xiao, Mengsu
    Liu, Jie
    FRONTIERS IN MEDICINE, 2023, 10
  • [39] Physician- and patient-reported outcomes in patients with moderate plaque psoriasis treated with apremilast during routine dermatology care in Germany
    Reich, K.
    Fritzlar, S.
    Korge, B.
    Manasterski, M.
    Schwichtenberg, U.
    Morys, S.
    Lampl, M.
    Roemmler-Zehrer, J.
    Gomez, Nunez N.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 123 - 124
  • [40] Maintenance of response in patients with moderate-to-severe plaque psoriasis treated with mirikizumab and retreatment response after loss of efficacy
    Reich, Kristian
    Papp, Kim A.
    Leonardi, Craig
    Menter, Alan
    Li, Joanne
    Tuttle, Jay
    Patel, Dipak
    Arora, Vipin
    Friedrich, Stuart
    Bissonnette, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB236 - AB236